Meeting
2024 ASCO Annual Meeting
Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).
Authors
Aaron Scott Mansfield
Mayo Clinic, Rochester, MN
Aaron Scott Mansfield , Xiaofei F. Wang , Dennis A. Wigle , Colleen Watt , Kathryn Kelley , Gregory A. Masters , Stephanie A. Berg , David E. Kozono , Tom Stinchcombe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Mesothelioma
Clinical Trial Registration Number
NCT05647265
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS8125)
DOI
10.1200/JCO.2024.42.16_suppl.TPS8125
Abstract #
TPS8125
Poster Bd #
382a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).
First Author: Aaron Scott Mansfield
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Initial findings from the DREAM-GI national database: Assessing the efficacy and safety of neoadjuvant immunotherapy (NIT) in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastrointestinal (GI) cancer.
First Author: Sakti Chakrabarti
Poster
2020 ASCO Virtual Scientific Program
Trial in progress: Neoadjuvant immune checkpoint blockade in resectable malignant pleural mesothelioma.
First Author: Joshua E. Reuss
Poster
2020 ASCO Virtual Scientific Program
Final results of a randomized, open label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.
First Author: Ahmed Omar Kaseb